Peptidomimetic GnRH receptor antagonists for the treatment of reproductive and proliferative diseases

Expert Opinion on Therapeutic Patents

Volumn 16, Issue 6, 2006, Pages 733-751

  Sarma, Pakala K S ^a   Tiwari, Atul ^b   Kondaskar, Atul ^a   Cliffe, Ian A ^a  

^a RANBAXY RESEARCH LABORATORIES   (India)

^b JUBILANT BIOSYS LTD   (India)

Author keywords

GnRH receptor; LHRH receptor; Peptidomimetics; Reproductive disease conditions

Indexed keywords

11,12 CYCLIC CARBAMATE; 3 (N BENZYL N METHYLAMINOMETHYL) 7 (2,6 DIFLUOROBENZYL) 4,7 DIHYDRO 2 (4 ISOBUTYRYLAMINOPHENYL) 4 OXOTHIENO[2,3 B]PYRIDINE 5 CARBOXYLIC ACID ISOPROPYL ESTER; 4 ALKOXY 7 CHLOROQUINOLONE; AMIDE; BENZIMIDAZOLE DERIVATIVE; CLARITHROMYCIN DERIVATIVE; FURAN 2 CARBOXAMIDE; G PROTEIN COUPLED RECEPTOR; GONADORELIN; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR AGONIST; GONADORELIN RECEPTOR ANTAGONIST; HORMONE RECEPTOR BLOCKING AGENT; HORMONE RECEPTOR STIMULATING AGENT; INDOLE DERIVATIVE; LEUPRORELIN; MACROLIDE; NBI 42902; NBI 56418; NEUROCRINE; PEPTIDE; PHTHALAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIMIDINONE DERIVATIVE; PYRROLE DERIVATIVE; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE; SUFUGOLIX; UNCLASSIFIED DRUG; UNINDEXED DRUG; URACIL DERIVATIVE;

BREAST CANCER; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG STRUCTURE; ENDOMETRIOSIS; GENITAL SYSTEM DISEASE; GONADORELIN RELEASE; HORMONE RECEPTOR INTERACTION; HUMAN; HYPOPHYSIS; HYPOTHALAMUS; MEDICAL LITERATURE; NONHUMAN; OVARY CANCER; PRECOCIOUS PUBERTY; PROSTATE CANCER; PROSTATE HYPERTROPHY; REPRODUCTION; REVIEW; SKIN MANIFESTATION; SKIN NODULE; UTERUS MYOMA;

EID: 33745649665     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.16.6.733     Document Type: Review

References (88)

1. SCHALLY AV: Hypothalamic hormones from neuro-endocrinology to cancer therapy. Anti-Cancer Drugs (1994) 5:115-130.
2. STANISLAUS D, PINTER JH, JANOVICK JA, CONN PM: Mechanisms mediating multiple physiological responses to gonadotropin-releasing hormone. Mol. Cell. Endocrinol. (1998) 144:1-10.
3. MILLAR RP, LU Z, PAWSON AJ et al. Gonadotropin-releasing hormone receptors. Endocrine Rev. (2005) 25:235-275.
4. FINK G: Gonadotropin secretion and its control. In: The Physiology of Reproduction, Knobil E, Neill J (Eds.), Raven Press, New York (1988):1349-1377.
5. SCHALLY AV, NAIR RM, REDDING TW, ARIMURA A: Isolation of the lutenizing hormone and follicle-stimulating hormone-releasing hormone from porcine hypothalami. J. Biol. Chem. (1971) 246:7230-7236.
6. AMOS M, BURGUS R, BLACKWELL R et al.: Purification, amino acid composition and N terminus of the hypothalamic lutenizing hormone releasing factor (LRF) of bovine origin. Biochem. Biophys. Res. Commun. (1971) 44:205-210.
7. RAMAKRISHNAPPA N, RAJAMAHENDRAN R, LIN YM, LEUNG PCK. GnRH in non-hypothalamic reproductive tissues. Anim. Reprod. Sci. (2005) 88:95-113.
8. POWELL JF, ZOHAR Y, ELIZUR A et al.: Three forms of gonadotropin-releasing hormone characterized from brains of one species. Proc. Natl. Acad. Sci. USA (1994) 91:12081-12085.
9. MIYAMOTO K, HASEGAWA Y, NOMURA M et al.: Identification of a second gonadotropin releasing hormone in chicken hypothalamus: evidence that gonadotropin secretion is probably controlled by two distinct gonadotropin-releasing hormones in avian species. Prod. Natl. Acad. Sci. USA (1984) 81:3874-3878.
10. WHITE RB, EISEN JA, KASTEN TL, FERNALD RD: Second gene for gonadotropin-releasing hormone in humans. Proc. Natl. Acad. Sci. USA (1998) 95:305-309.
11. LEUNG PC, CHENG CK, ZHU XM: Multi-factorial role of GnRH-I and GnRH-II in the human ovary. Mol. Cell. Endocrinol. (2003) 202:145-153.
12. TOBERT SA, CHICKERING TW, SOWER SA. Relationship of gonadotropin-releasing hormone (GnRH) neurons to the olfactory system in developing lamprey (petromyzon marinus). J. Comp. Neurol. (1996) 376:97-111.
13. YANG-FENG TI, SEEBURG PH, FRANCKE U: Human lutenizing hormone-releasing hormone gene (LHRH) is located on short arm of chromosome 8 (region 8p11.2-p21). Somat. Cell. Mol. Genet. (1986) 12:95-100.
14. SEALFON SC, WEINSTEIN H, MILLAR RP: Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. Endocr. Rev. (1997) 18:180-205.
15. MILLAR RP: GnRHs and GnRH receptors. Anim. Reprod. Sci. (2005) 88:5-28.
16. MILLAR RP, LOWE S, CONKLIN D et al.: A novel mammalian receptor for the evolutionary conserved Type II GnRH. Proc. Natl. Acad. Sci. USA (2001) 98:9636-9641.
17. MORGAN K, CONKLIN D, PAWSON AJ et al.: A transcriptionally active human Type II gonadotropin releasing hormone receptor gene homologue overlaps two genes in the antisense orientation on chromosome 1q. 12. Endocrinology (2003) 144:423-436.
18. MAUDSLEY S, DAVIDSON L, PAWSON AJ et al.: Gonadotropin Releasing Hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Gxi-coupling state of the Type I GnRH receptor. Cancer Res. (2004) 64:7533-7544.
19. MILLAR RP, PAWSON AJ: Outside in and inside out signaling. the new concept that selectivity of ligand binding at the GnRH receptor is modulated by the intracellular environment. Endocrinology (2004) 145:3590-3593.
20. MILLAR RP: GnRH II and Type II GnRH receptors. Trends Endocrinol. Metab. (2002) 14:35-43.
21. STOJILKOVIC SS, REINHART J, CATT KJ: Gonadotropin-releasing hormone receptors: structure and signal transduction pathways. Endocr. Rev. (1994) 15:462-499.
22. KAISER UB, CONN PM, CHIN WW: Studies of gonadotropin-releasing hormone (GnRH) action using GnRH receptor-expressing pituitary cell lines. Endocr. Rev. (1997) 18:46-70.
23. TIWARI A, KRISHNA NS, NANDA K, CHUGH A: Benign prostatic hyperplasia: an insight into current investigational medical therapies. Expert Opin. Investig. Drugs (2005) 14:1359-1372.
24. CONN PM, CROWLEY WF Jr: Gonadotropin-releasing hormone and its analogs. Ann. Rev. Med. (1994) 45:391-405.
25. KARTEN MJ, RIVIER JE: Gonadotropin-releasing hormone analog design-structure-function studies towards the development of agonists and antagonists: rationale and perspective. Endocr. Rev. (1986) 7:44-66.
26. CROOK T, SHERIDAN WP: Development of GnRH receptor antagonists for prostate cancer: New approaches to treatment. Oncologist (2000) 5:162-168.
27. HUIRNE JA, LAMBALK CB: Gonadotropin-releasing-hormone-receptor antagonists. Lancet (2001) 358:1793-1803.
28. BAJUSZ S, KOVACS M, GAZDAG M et al.: Highly potent antagonists of lutenizing hormone-releasing hormone free of edematogenic effects. Proc. Natl. Acad. Sci. USA (1988) 85:1637-1641.
29. LJUNGQVIST A. FENG DM, HOOK W et al.: Antide and related antagonists of lutenizing hormone release with long action and oral activity. Proc. Natl. Acad. Sci USA (1988) 85:8236-8240.
30. NESTOR JJ Jr, TAHILRAMANI R, HO TL et al.: Potent gonadotropin releasing hormone antagonists with low histamine-releasing activity. J. Med. Chem. (1992) 35:3942-3948.
31. RIVIER J, PORTER J, HOEGER C et al.: Gonadotropin-releasing hormone antagonists with N-omega-triazolylornithine,-lysine, or -p-aminophenylalanine residues at position 5 and 6. J. Med. Chem. (1992) 35:4270-4278.
32. DEGHENGHI R, BOUTIGNON F, WUTHRICH P et al.: Antarelix (EP 24332) a novel water soluble LHRH antagonist. Biomed. Pharmacother. (1993) 47:107-110.
33. WECKERMANN D, HARZMANN R: Hormone therapy in prostate cancer. LHRH antagonists versus LHRH analogues. Eur. Urol. (2004) 46:279-284.
34. TARLATZIS BC, BILI H: Safety of GnRH agonists and antagonists. Expert Opin. Drug Saf. (2004) 3:39-46.
35. KIESEL L, THOMAS K, TEMPONE A et al.: Efficacy and safety of buserelin treatment in women with endometriosis-a multicentre open-label study. Gynecol. Endocrinol. (1989) 3(Suppl. 2):5-19.
36. GIULIANI A, SCHOELL W, AUNER J. URDL W- Controlled ovarian hyper-stimulation in assisted reproduction: effect on the immune system. Fertil. Steril. (1998) 70:831-835.
37. JIANG G, GAVINI E. DANI BA et al.: Identification and determination of GnRH anatagonist gelling at injection site. Int. J. Pharmaceutics (2002) 233:19-27.
38. TUCCI FC, CHEN C: Synthesis of orally active small-molecule gonadotropin-releasing hormone antagonists. Curr. Opin. Drug. Discov. Develop. (2004) 7:832-847.
39. ZHU YF, CHEN C: Recent advances in small molecule gonadotropin-releasing hormone receptor antagonists. Expert Opin. Ther. Patents (2004) 14:187-199.
40. ARMER RE, SMELT KH: Non-peptidic GnRH receptor antagonists. Curr. Med. Chem. (2004) 11:3017-3028.
41. ZHU YF, CHEN C, STRUTHERS RS: Nonpeptide gonadotropin releasing hormone antagonists. Ann. Rep. Med. Chem. (2004) 39:99-110.
42. CHO N, HARADA M, IMAEDA T et al.: Discovery of a novel, potent and orally active nonpeptidic antagonist of the human leutinizing hormone- releasing hormone (LHRH) Receptor. J. Med. Chem. (1998) 41:4190-4195.
43. ZHU YF, STRUTHERS RC, CONNORS PJ et al.: Initial structure-acitivity relationship studies of a novel series of pyrrolo[1,2-a]pyrimid-7-ones as GnRH receptor antagonists. Bioorg. Med. Chem. Lett. (2002) 12:399-402,
44. ZHU YF, WILCOXEN K, SAUNDERS J et al.: A novel synthesis of 2-aryl-pyrrolo[1,2-alpyrimid-7-ones and their structure-activity relationships as potent GnRH receptor antagonists. Bioorg. Med. Chem. Lett. (2002) 12:403-406.
45. TUCCI FC, ZHU YF, GUO Z et al.: A novel synthesis of 7-aryl-8-fluoro-pyrrolo[1,2-a]pyramid-4-ones as potent, stable GnRH receptor antagonists. Bioorq. Med. Chem. Lett. (2002) 12:3491-3495.
46. SASAKI S, IMAEDA T, HAYASE Y et al.: A new class of potent nonpeptide leuteinizing harmone releasing hormone (LHRH) antagonists: design and synthesis of 2-phenylimidazo[1,2-a]pyrimidin-5-ones. Bioorq. Med. Chem. Lett. (2002) 12:2073-2077.
47. WILCOXEN KM, ZHU YF, CONNORS PJ et al.: Synthesis and initial structure activity relationships of a novel series of imidazolo[1,2-alpyrimid-5-ones as potent GnRH receptor antagonists. Bioorg. Med. Chem. Lett. (2002) 12:2179-2183.
48. GROSS TD, ZHU YF, SAUNDERS J et al.: Design, synthesis and structure-activity relationships of novel imidazolo[1,2-a]pyrimid-5-ones as potent GnRH receptor antagonists. Bioorg. Med. Chem. Lett. (2002) 12:2185-2187.
49. ZHU YF, GUO Z, GROSS TD et al.: Design and structure-activity relationships of 2-alkyl-3-aminomethyl-6-(3-methoxyphenyl)-7-methyl-8-(2-fluombenzyl)- imidazolo[1,2-a]pyrimid-5-ones as potent GnRH receptor antagonists. J. Med. Chem. (2003) 46:1769-1772.
50. SORBERA LS, CASTANER J, LEESON PA. TAK-013. Drugs Future (2003) 28:121-124.
51. SASAKI S, CHO N, NARA Y et al.: Discovery of a thieno[2,3-d] pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: A highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone releasing hormone receptor. J. Med. Chem. (2003) 46:113-124.
52. NO AUTHORS LISTED: SUFUGOLIX: IddB Drug Report, RF 615297.
53. GUO Z, CHEN Y, WU D et al.: Synthesis and structure activity relationships of thieno[2,3-d]pyrimidine-2,4-dione derivatives as potent GnRH receptor antagonists. Bioorg. Med. Chem. Lett. (2003) 13:3617-3622.
54. ZHU YF, GROSS TD GUO Z et al.: Identification of I-arylmethyl-3-(2-aminoethyl)-5-aryluracil as novel gonadotropin-releasing-hormone receptor antagonists. J. Med. Chem. (2003) 46:2023-2026.
55. GUO Z, ZHU YF, TUCCI FC et al.: Synthesis and structure activity relationships of I-arylmethyl-3-(2-aminopmpyl)-5-aryl-6-methyluracils as potent GnRH receptor antagonists. Bioorg. Med. Chem. Lett. (2003) 13:3311-3315.
56. TUCCI FC, ZHU YF, GUO Z et al.: Synthesis and structure activity relationships of I-arylmethyl-3-(1-methyl-2-amino)ethyl-5-aryl-methyluracils as antagonists of the human GnRH receptor. Bioorg. Med. Chem. Lett. (2003) 13:3317-3322.
57. GUO Z, ZHU YF, GROSS TD et al.: Synthesis and structure activity relationships of 1-arylmethyl-5-aryl-6-methyluracils as potent gonadotropin-releasing-hormone receptor antagonists. J. Med. Chem. (2004) 47:1259-1271.
58. TUCCI FC, ZHU YF, GUO Z et al.: 3-(2-Aminoalkyl)-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)- 6-methyluracils as orally bioavailable antagonists of the human gonadotropin releasing hormone receptor. J. Med. Chem. (2004) 47:3483-3486.
59. ROWBOTTOM MW, TUCCI FC, ZHU YF et al.: Synthesis and structure activity relationships of (R)-1-alkyl-3-[2-(2-amino)phenethyl]-5-(2-fluorophenyl)- 6-methyluracils as human GnRH receptor antagonists. Bioorg. Med. Chem. Lett. (2004) 14:2269-2274.
60. ROWBOTTOM MW, TUCCI F C, CONNORS PJ Jr et al.: Synthesis and structure activity relationships of uracil derived human GnRH receptor antagonists: (R)-3-[2-(2-amino)phenethyl]-1-(2,6-difluorobenzyl)-6-methyluracils containing a substituted thiophene or thiazole at C-5. Bioorg. Med. Chem. Lett. (2004) 14:4967-4973.
61. TUCCI FC, ZHU YF, STRUTHERS RS et al.: 3-[(2R)-Amino-2-phenethyl]-l-(2,6-difluorobenzyl)-5-(2-fluoro-3- methoxyphenyl)-6-methyl-pyrimidin-2,4-dione (NBI 42902) as a potent and orally active antagonist of the human gonadotropin releasing hormone receptor. Design, synthesis, and in vitro and in vivo characterization. J. Med. Chem. (2005) 48:1169-1178.
62. GUO Z, CHEN Y, HUANG CQ et al.: Uracils as potent antagonists of the human gonadotropin releasing hormone receptor without atropisomerism. Bioorg. Med. Chem. Lett. (2005) 15:2519-2522.
63. PONTILLO J, GUO Z, WU D, STRUTHERS RC, CHEN C: Synthesis of aryl-1,2,4-triazine-3,5-diones as antagonists of the gonadotropin-releasing hormone receptor. Bioorg. Med. Chem. Lett. (2005) 15:4363-4366.
64. GUO Z, WU D, ZHU YF et al.: A convenient one-pot synthesis of asymmetric 1,3,5-triazine-2,4,6-triones and its application towards a novel class of gonadotropin releasing hormone receptor antagonists. Bioorg. Med. Chem. Lett. (2005) 15:693-698.
65. PONTILLO J, CHEN C: Efficient synthesis of bicyclic oxazolino- and thiazolino[3,2-c]pyrimidine-5,7-diones and its application to the synthesis of GnRH receptor antagonists. Bioorg. Med. Chem. Lett. (2005) 15:1407-1411.
66. PELLETIER JC, CHENGALVALA M, COTTOM J et al.: 2-Phenyl-4-piperazinylbenzimidazoles as inhibitors of the gonadotropin releasing hormone (GnRH) receptor. ACS (2005) 230:Washington.
67. NO AUTHORS LISTED: IddB drug report: NBI-56418, Neurocrine Biosciences Incorporation.
68. CHU L, HUTCHINS JE, WEBER AE et al.: Initial structure-activity relationship of a novel class of nonpeptidyl GnRH receptor antagonists: 2-Arylindoles. Bioorg. Med. Chem. Lett. (2001) 11:509-513.
69. LIN P, MARINO D, LO J-L et al.: 2-(3,5-Dimethylphenyl)tryptamine derivatives that bind to the GnRH receptor. Bioorg. Med. Chem. Lett. (2001) 11:1073-1076.
70. CHU L, LO J-L, YANG YT et al.: SAR studies of novel 5-substituted-2-arylindoles as nonpeptidyl GnRH receptor antagonists. Bioorq. Med. Chem. Lett. (2001) 11:515-517.
71. ASHTON WT, SISCO RM, YANG YT et al.: Substituted indole-5-carboxamides and -acetamides as potent nonpeptide GnRH receptor antagonists. Bioorg. Med. Chem. Lett. (2001) 11:1723-1726.
72. LIN P, PARIKH M, LO J-L et al.: Heterocyclic derivatives of 2-(3,5-dimethylphenyl)tryptamine as GnRH receptor antagonists. Bioorg. Med. Chem. Lett. (2001) 11:1077-1080.
73. ASHTON WT, SISCO RM, YANG YT et al.: Potent nonpeptide GnRH receptor antagonists derived from substituted indole-5-carboxamides and -acetamides bearing a pyridine side chain terminus. Bioorg. Med. Chem. Lett. (2001) 11:1727-1731.
74. ASHTON WT, SISCO RM, KIECZYKOWSKI GR et al.: Orally bioavailable, indole-based nonpeptide GnRH receptor antagonists with high potency and hinctional activity. Bioorg. Med. Chem. Lett. (2001) 11:2597-2602.
75. YOUNG JR, HUANG SX, WALSH TF et al.: 2-Arylindoles as gonadotropin releasing harmone (GnRH) antagonists: Optimization of the tryptamine side chain. Bioorg. Med. Chem. Lett. (2002) 12:827-832.
76. SIMEONE JP, BUGIANESI RL, PONPIPOM MM et al.: Modification of the pyridine moiety of non-peptidyl indole GnRH receptor antagonists. Bioorg. Med. Chem. Lett. (2002) 12:3329-3332.
77. UJJAINWALA F, WALSH TF et al.: Total syntheses of 6- and 7-azaindole derived GnRH receptor antagonists. Tet. Lett. (2001) 42:6441-6445.
78. DEVITA RJ, WALSH TF, YOUNG JR et al.: A potent nonpeptidyl 1H-quinolone antagonist for the gonadotropin releasing harmone receptor. J. Med. Chem. (2001) 44:917-922.
79. JIANG J, DEVITA RJ, GOULET MT et al.: Synthesis and structure-activity relationship studies of piperidine substituted quinolones as nonpeptide gonadotropin releasing harmone antagonist. Bioorg. Med. Chem. Lett. (2004) 14:1795-1798.
80. DEVITA RJ, PARICH M, JIANG J et al.: Identification of neutral 4-o-alkyl quinolone nonpeptide GnRH receptor antagonists. Bioorg. Med. Chem. Lett. (2004) 14:5599-5603.
81. LUTIHN DR, HONG Y, PATHAK VP et al.: The discovery of novel small molecule non-peptide gonadotropin releasing harmone (GnRH) receptor antagonists. Bioorg. Med. Chem. Lett. (2002) 12:3467-3470.
82. LUTIHN DR, HONG Y, TOMPKINS E et al.: Characterization of mono- and diaminopyrimidine derivatives as novel, non-peptide gonadotropin releasing hormone (GnRH) receptor antagonists. Bioorg. Med. Chem. Lett. (2002) 12:3635-3639.
83. ANDERS KI, LUTHIN DR, CASTILLO R et al.: Biological characterization of a novel, orally active small molecule gonadotropin-releasing hormone (GnRH) antagonist using castrated and intact rats. J. Pharmacol Exp. Ther. (2003) 305:688-695.
84. HASHIMOTO K, TATSUTA M, KATAOKA M et al.: Benzimidazole derivatives as novel non-peptide luteinizing hormone releasing hormone (LHRH) antagonists. Part 1: Benzimidazole-5-sulfonamides. Bioorg. Med. Chem. Lett. (2005) 15:799-803.
85. LI Y, KATAOKA M, TATSUTA M et al.: Benzimidazole derivatives as novel non-peptide luteinizing hormone releasing hormone (LHRH) antagonists. Part 2: Benzimidazole-5-sulfonamides. Bioorg. Med. Chem. Lett. (2005) 15:805-807.
86. TATSUTA M, KATAOKA M, YASOSHIMA K et al.: Benzimidazoles as non-peptide luteinizing hormone-releasing hormone (LHRH) antagonists. Part 3: Discovery of 1-(1H-benzimidazol-5-yl)-3-tert-butyl-urea derivatives. Bioorg. Med. Chem. Lett. (2005) 15:2265-2269.
87. RANDOLPH JT, WAID P, NICHOLAS C et al.: Nonpeptide luteinizing hormone-releasing hormone (LHRH) antagonists derived from erythromycin A: Design, synthesis and biological activity of cladinose replacement analogues. J. Med. Chem. (2004) 47:1085-1097.
88. RANDOLPH JT, SAUER DR, HAVIV F et al.: Elimination of antibacterial activities of nonpeptide luteinizing hormone-releasing hormone (LHRH) antagonists derived from erythromycin A. Bioorg. Med. Chem. Lett. (2004) 14:1599-1602.